Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 2, 2012, Pages 161-176

  Kimko, Holly ^a   Gibiansky, Ekaterina ^b   Gibiansky, Leonid ^b   Starr, H Lynn ^a   Berwaerts, Joris ^a   Massarella, Joseph ^a   Wiegand, Frank ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b QuantPharm LLC 49 Flints Grove Drive   (United States)

Author keywords

Attention deficit hyperactivity disorder; Meta analysis; Methylphenidate pharmacodynamics; Placebo model; Population modeling

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MEGADOSE; DRUG RELEASE; DRUG TOLERANCE; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; MORNING DOSAGE; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861475769     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-011-9238-9     Document Type: Article

References (22)

1. Samtani MN (2010) Simple pharmacometric tools for oral antidiabetic drug development: competitive landscape for oral noninsulin therapies in Type 2 diabetes. Biopharm Drug Dispos 31:162-177
2. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T (2010) Alzheimer's Disease Working Group. Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement 6:39-53
3. Luu KT, Raber SR, Nickens DJ, Vicini P (2010) A model-based meta-analysis of the effect of Latanoprost chronotherapy on the circadian intraocular pressure of patients with glaucoma or ocular hypertension. Clin Pharmacol Ther 87(4):421-425
4. Mandema JW, Cox E, Alderman J (2005) Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain - results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia 25:715-725 (Pubitemid 41208313)
5. Mandema JW, Hermann D, Wang W, Sheiner T, Milad M, Bakker-Arkema R, Hartman D (2005) Model-based development of gemcabene, a new lipid-altering agent. AAPS J 7(3):E513-E522
6. Ahn JE, French JL (2010) Longitudinal aggregate data modelbased meta-analysis with NONMEM: approaches to handling within treatment arm correlation. J Pharmacokinet Pharmacodyn 37:179-201
7. Kimko HC, Cross JT, Abernethy CD (1999) Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 37(6):457-470 (Pubitemid 30032250)
8. Wigal SB, Gupta S, Heverin E, Starr HL (2011) Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 21(3):255-263
9. Swanson JM (2002) School-Based assessments and interventions for ADD students. KC Publishing, Irvine
10. Swanson J, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, Williams L, Shoulson I, Wigal S (1999) Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 66(3):295-305 (Pubitemid 29451762)
11. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ (2004) COMACS Study Group. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113(3 Pt 1):e206-e216
12. Brams M, Muniz R, Childress A, Giblin J, Mao A, Turnbow J, Borrello M, McCague K, Lopez FA, Silva R (2008) A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect. CNS Drugs 22(8):693-704 (Pubitemid 351950099)
13. Muniz R, Brams M, Mao A, McCague K, Pestreich L, Silva R (2008) Efficacy and safety of extended-release dexmethylphenidate compared with d, l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol 18(3):248-256
14. Lopez F, Silva R, Pestreich L, Muniz R (2003) Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs 5(8):545-555 (Pubitemid 37046766)
15. Silva R, Muniz R, McCague K, Childress A, Brams M, Mao A (2008) Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and d, l-Methylphenidate and Placebo in a laboratory classroom setting. Psychopharmacol Bull 41(1):19-33
16. Silva RR, Muniz R, Pestreich L, Childress A, Brams M, Lopez FA, Wang J (2006) Efficacy and duration of effect of extendedrelease dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 16(3):239-251 (Pubitemid 43902421)
17. Meeting of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology April 13, 2010, BRIEFING INFORMATION p 32 http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM207955. pdf (Accessed June 20, 2011)
18. Tuerck D, Appel-Dingemanse S, Maboudian M, Pommier F, Wang Y, Sedek G (2007) Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. J Clin Pharmacol 47(1):64-69 (Pubitemid 44973999)
19. Gonzalez MA, Pentikis HS, Anderl N, Benedid MF, DeCory HH, Hirshey Dirksen SJ, Hatch SJ (2002) Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 40(4):175-184 (Pubitemid 34296385)
20. Handen BL, Janosky J, McAuliffe S, Breaux AM, Feldman H (1994) Prediction of response to methylphenidate among children with ADHD and mental retardation. J Am Acad Child Adolesc Psychiatry 33(8):1185-1193 (Pubitemid 24296836)
21. Hermens DF, Cooper NJ, Kohn M, Clarke S, Gordon E (2005) Predicting stimulant medication response in ADHD: evidence from an integrated profile of neuropsychological, psychophysiological and clinical factors. J Integr Neurosci 4(1):107-121 (Pubitemid 40645299)
22. Sonuga-Barke EJS, Swanson JM, Coghill D, DeCory HH, Hatch SJ (2004) Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: Preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 4:28